Related Experiment Videos
[Heavy chain disease]
Insights
Heavy chain diseases (HCDs) are rare lymphoproliferative disorders involving incomplete antibody heavy chains. Alpha-HCD is most common, affecting the digestive tract, while gamma-HCD and mu-HCD present differently.
Area of Science:
- Immunology
- Hematology
- Oncology
Context:
- Heavy chain diseases (HCDs) are a group of rare lymphoproliferative disorders.
- These conditions are defined by the production of monoclonal, incomplete immunoglobulin heavy chains lacking light chains.
- HCDs encompass gamma-HCD, alpha-HCD, and mu-HCD, each with distinct characteristics.
Purpose:
- To describe the characteristics and clinical presentations of various heavy chain diseases.
- To differentiate between the subtypes of HCDs based on their affected immunoglobulin class and clinical patterns.
- To highlight recent associations of heavy chain abnormalities with amyloidosis and deposition diseases.
Summary:
- Heavy chain diseases (HCDs) are characterized by the synthesis of truncated heavy chains without associated light chains.
- Gamma-HCD exhibits variable clinical features, whereas alpha-HCD predominantly affects the secretory IgA system and the digestive tract with a uniform clinical pattern.
- Alpha-HCD is the most prevalent subtype, while mu-HCD is rare and may be indicated by Bence Jones proteins and specific bone marrow findings.
- Recent research has linked molecular abnormalities of heavy chains to heavy-chain-associated amyloidosis and heavy chain deposition disease.
Impact:
- Provides a comprehensive overview of HCDs, aiding in their diagnosis and classification.
- Enhances understanding of the specific clinical manifestations of alpha-HCD, facilitating targeted patient management.
- Contributes to the differential diagnosis of lymphoproliferative disorders and related conditions like amyloidosis.
Abstract:
Heavy chain diseases (HCDs) are monoclonal, lymphoproliferative disorders characterized by the production of incomplete heavy chains, devoid of light chains. Since the first report of gamma-HCD in 1964, alpha-HCD and mu-HCD have also been described. The clinical features of gamma-HCD may vary considerably. In contrast, alpha-HCD primarily involves the secretory IgA system and mainly the digestive tract. Its clinical pattern is strikingly uniform. alpha-HCD is the most common of the HCDs, while mu-HCD is relatively rare. The demonstration of Bence Jones proteins in the urine in association with lymphoproliferative disorders and vacuolated plasma cells in the bone marrow deserves further investigation for mu-HCD. Recently, two disease entities related to molecular abnormalities of heavy chains have been reported; heavy-chain-associated amyloidosis and heavy chain deposition disease.